前列腺癌
雄激素受体
紫杉烷
医学
雄激素
癌症研究
肿瘤科
内科学
阉割
疾病
癌症
卡巴齐塔塞尔
雄激素剥夺疗法
激素
乳腺癌
出处
期刊:NEJM evidence
[New England Journal of Medicine]
日期:2023-12-26
卷期号:3 (1)
摘要
Multiple therapeutic advances in recent years have significantly improved outcomes for patients with metastatic prostate cancer, including utilization of combination androgen receptor (AR) pathway inhibitors and/or taxane chemotherapy in earlier, hormone-sensitive disease.1 Unfortunately, patients typically still develop metastatic castration-resistant prostate cancer (mCRPC), the lethal form of disease with limited prognosis. Despite castration resistance, the majority of patients with mCRPC continue to have AR-dependent disease through a variety of mechanisms, including emergence of AR mutations, amplifications, splice variants, and persistent AR activation via alternative pathways of androgen production.2
科研通智能强力驱动
Strongly Powered by AbleSci AI